Press coverage about Vivus (NASDAQ:VVUS) has been trending positive on Saturday, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vivus earned a media sentiment score of 0.35 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 48.4350731545236 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
A number of brokerages have weighed in on VVUS. ValuEngine lowered Vivus from a “sell” rating to a “strong sell” rating in a report on Monday, April 2nd. Zacks Investment Research downgraded shares of Vivus from a “buy” rating to a “hold” rating in a research report on Saturday, January 6th.
VVUS stock opened at $0.38 on Friday. Vivus has a 12-month low of $0.33 and a 12-month high of $1.38. The company has a debt-to-equity ratio of -24.71, a current ratio of 6.80 and a quick ratio of 6.34. The company has a market cap of $40.32, a PE ratio of -1.30 and a beta of 0.61.
Vivus (NASDAQ:VVUS) last posted its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.03. Vivus had a negative net margin of 46.67% and a negative return on equity of 843.43%. The company had revenue of $11.94 million during the quarter. analysts forecast that Vivus will post -0.45 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Vivus (NASDAQ:VVUS) Getting Positive Press Coverage, Analysis Finds” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/positive-news-coverage-somewhat-unlikely-to-impact-vivus-vvus-share-price.html.
VIVUS, Inc, a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Receive News & Ratings for Vivus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivus and related companies with MarketBeat.com's FREE daily email newsletter.